+91 8617752708

British Journal of Medicine and Medical Research, ISSN: 2231-0614,Vol.: 4, Issue.: 1 (01-10 January)

Short Communication

Glycogen Synthase Kinase-3β Expression and Phosphorylation in Peripheral Blood Mononuclear Cells of Patients with Amyotrophic Lateral Sclerosis


Miguel González-Muñoz1,2*, Ana I. Rodríguez-Mahillo3, Carmen Gil4, Yolanda Morán1, Ignacio Moneo2, Ana Martínez4 and Jesús S. Mora1

1ALS Unit, Hospital Carlos III, Sinesio Delgado 10, 28029, Madrid, Spain.
2Department of Immunology, Hospital Carlos III, Sinesio Delgado 10, 28029, Madrid, Spain.
3Fundación para la Investigación Biomédica, Sinesio Delgado 10, 28029, Madrid, Spain.
4Instituto de Química Médica-CSIC, Juan de la Cierva 3, 28006, Madrid, Spain.

Article Information


(1) Salomone Di Saverio, Emergency Surgery Unit, Department of General and Transplant Surgery, S. Orsola Malpighi University Hospital, Bologna, Italy.

(2) Jimmy T. Efird, Department of Public Health, Director of Epidemiology and Outcomes Research, East Carolina Heart Institute, Brody School of Medicine, Greenville, North Carolina, USA.


(1) Anonymous.

(2) Honglin Feng, Jing Wang, The First Affiliated Hospital, Harbin Medical University, Harbin, China,

(3) Anonymous.

(4) Anonymous.

Complete Peer review History: http://www.sciencedomain.org/review-history/2020


Aims: To quantify total glycogen synthase kinase (GSK)-3β and GSK-3β phosphorylated at serine 9 in the peripheral blood mononuclear cells from Amyotrophic Lateral Sclerosis (ALS) patients and to assess if GSK-3β could be a biomarker for ALS.
Study Design: Cross-sectional observational study.
Place and Duration of Study: Department of Immunology and Amyotrophic Lateral Sclerosis Unit, Hospital Carlos III, Madrid, Spain, between February 2011 and August 2012.
Methodology: Blood samples were drawn from 44 ALS patients and 41 healthy controls. Peripheral blood mononuclear cells were isolated and cellular extracts were obtained to assess GSK-3β and serine 9 phosphorylated GSK-3β concentrations. Enzymes were measured by a quantitative enzyme-linked immunoassay in the peripheral blood mononuclear cell extracts. Patients were divided into two groups according to the Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R) median value for the comparative analysis.
Results: Patients (n=22) showing a high functional impairment (ALSFRS-R ≤ 32) had GSK-3β levels (11.2±3.6 pg/μg protein) higher than healthy controls (8.7±4.7 pg/μg protein; P=0.04) and than those patients (n=22) with ALSFRS-R > 32 (6.9±4.4 pg/μg protein; P<0.01). A negative correlation between GSK-3β concentration and ALSFRS-R values (r = −0.39; P=0.006) was also observed.
Conclusion: Our results show that GSK-3β expression is altered in non-neural cells of ALS patients and suggest that its overexpression may play a role in the pathogenesis of ALS. The quantification of GSK-3β in peripheral blood mononuclear cells may be used as a potential biomarker of ALS progression.

Keywords :

Amyotrophic lateral sclerosis; glycogen synthase kinase-3β; peripheral blood mononuclear cells; biomarker.

Full Article - PDF    Page 263-271

DOI : 10.9734/BJMMR/2014/5578

Review History    Comments

Our Contacts

Guest House Road, Street no - 1/6,
Hooghly, West Bengal,

+91 8617752708


Third Floor, 207 Regent Street
London, W1B 3HH,

+44 20-3031-1429